

Supplemental Material

Text S1. Estimating diagnosis delays

From the annual sex-, age-, HIV testing history-, and CD4 cell count-specific testing rates, we calculated several cross-sectional indicators using period life table methods¹⁷ that account for the competing risk of AIDS-related death. For each stratum, we proceed by initializing the life table at infection (time 0: t_0) using the age-specific CD4 cell count distribution at infection (either ≥ 500 or 350-499 CD4 cells per μL) as is used in Spectrum. We then calculate the number of individuals that will either receive a positive test result or die of AIDS-related cause at each time step ($\Delta t = 0.1$ year), accounting for CD4 cell count progression. As these are period life tables, estimates reflect the distribution of time to diagnosis if a person who seroconverted in year y experienced the HIV testing rates by age and CD4 category estimated for the that year for their remaining lifetime. Specifically, the life tables are constructed using the following equations (for $t \geq t_0$):

$$I_{y(t+\Delta t)}^{kisu} = \begin{cases} I_{yt}^{kisu} - \left((\tau_y^{ki[t]s[t]u} + \epsilon_{is[t]} + \gamma^{is}) I_{yt}^{kisu} \right) \Delta t; & \text{if } s = 1 \\ I_{yt}^{kisu} + \left(\gamma^{i(s-1)} I_{yt}^{ki(s-1)u} - (\tau_y^{ki[t]s[t]u} + \epsilon_{is[t]} + \gamma^{is}) I_{yt}^{kisu} \right) \Delta t; & \text{if } 1 < s < 7 \\ I_{yt}^{kisu} + \left(\gamma^{i(s-1)} I_{yt}^{ki(s-1)u} - (\tau_y^{ki[t]s[t]u} + \epsilon_{is[t]}) I_{yt}^{kisu} \right) \Delta t; & \text{if } s = 7 \end{cases}$$

where I_{yt}^{kisu} is the number of individuals who seroconverted during calendar year y , from sex k , age i , CD4 cell count s (where 1 indexes CD4 counts of ≥ 500 cells per μL , 2 for 350-499, 3 for 250-349, 4 for 200-249, 5 for 100-199, 6 for 50-99, and 7 for < 50 CD4 cells per μL), and testing history u , at time t since infection; γ^{is} is the CD4 cell count progression rates; $\tau_y^{ki[t]s[t]u}$ is the HIV testing rate specific to sex k , age $(i_{[t]})$, accounting for aging as a function of time t); CD4 cell count ($s_{[t]}$), as CD4 cell count decreases as a function of time t), and testing history (u) that were estimated for the calendar year y in which an individual seroconverted; and $\epsilon_{is[t]}$ is the age- (at infection) and CD4 cell count-specific AIDS-related mortality rate.

After constructing the life table, we calculated the median time between HIV infection and diagnosis or AIDS-related death (m_y^{kisu}) by finding the time t after which more than half of the newly seroconverted individuals had either been diagnosed or died of HIV ($d_y^{kisu}(t)$):

$$d_y^{kisu}(t) = \frac{\sum_{t_0}^t \sum_s \left(\left(\tau_y^{ki[t]s[t]u} + \epsilon_{is[t]} \right) I_{yt}^{kisu} \right) \Delta t}{\sum_s I_{yt_0}^{kisu}}$$

$$m_y^{kisu} = \min_{t>0} \{ |d_y^{kisu}(t) - 0.5| \}$$

Finally, the probability of getting tested within one year of infection (p_y^{kisu}), and of getting tested before reaching a CD4 cell count threshold lower than 350 cells per μL ($s=3$) (c_y^{kisu}) were estimated by accounting for the competing risk of AIDS-related death using, respectively:

$$p_y^{kisu} = \frac{\sum_{t_0}^1 \sum_s \left(\tau_y^{ki[t]s[t]u} I_{yt}^{kisu} \Delta t \right)}{\sum_s I_{yt_0}^{kisu}}$$

$$c_y^{kisu} = \frac{\sum_s^3 \sum_t \left(\tau_y^{ki[t]s[t]u} I_{yt}^{kisu} \Delta t \right)}{\sum_s I_{yt_0}^{kisu}}$$

For each calendar year between 2000 and 2020, we estimated these indicators for the 16 age/sex/testing history strata separately. They were then aggregated to the desired level of aggregation (e.g., age, sex, country, region) by weighting each stratum by the estimated number of new HIV infections in that stratum for that year (obtained from Spectrum).


Text S2. Comparison of calibrated *Shiny90* model fits with programmatic and survey data for each of the 40 included sub-Saharan countries, 2000-2020

For each country, *Shiny90* posterior estimates of the total number of HIV tests (A), the total number of positive tests (B), the proportion reporting having ever been tested among the HIV negative population (C), among people living with HIV (PLHIV; D), and overall (E) are compared to available HTS program and survey data. On all graphs, the lines correspond to the median of the posterior estimates, whereas the shaded areas correspond to the 95% credible intervals. Black dots on graphs A and B correspond to the HIV testing services program data for the overall number of tests, and for the number of positive tests, respectively. The points on the graphs C to E represent the survey estimates of the proportion of men (circles) and women (squares) reporting having ever been tested among the HIV negative population (C), the PLHIV (D), and overall (E). The lines crossing the points correspond to the 95% confidence intervals of the surveys estimates. For countries denoted by *, surveys for which datasets are not available but are included in knowledge of status estimates reported to UNAIDS are not plotted.


Contents

Angola	3
Benin	4
Botswana	5
Burkina Faso	6
Burundi	7
Cameroon*	8
Chad	9
Comoros	10
Congo	11
Côte d'Ivoire*	12
Democratic Republic of the Congo	13
Equatorial Guinea	14
Eritrea	15
eSwatini	16
Ethiopia	17
Gabon	18
Gambia	19
Ghana	20
Guinea	21
Kenya*	22
Lesotho*	23
Liberia	24
Madagascar	25
Malawi	26
Mali	27
Mauritania	28
Mozambique	29
Namibia*	30
Niger	31
Nigeria	32
Rwanda*	33
Senegal	34
Sierra Leone	35
South Africa	36
South Sudan	37
Tanzania	38
Togo	39
Uganda*	40
Zambia	41
Zimbabwe*	42


Angola




Benin




Botswana




Burkina Faso




Burundi




Cameroon*




Chad








Comoros




Congo








Côte d'Ivoire (Ivory Coast)*




Democratic Republic of the Congo




Equatorial Guinea




Eritrea




eSwatini




Ethiopia




Gabon




Gambia




Ghana




Guinea




Kenya*




Lesotho*




Liberia




Madagascar




Malawi




Mali




Mauritania




Mozambique




Namibia*




Niger




Nigeria




Rwanda*








Senegal




Sierra Leone




South Africa




South Sudan




Tanzania




Togo




Uganda*



Zambia



Zimbabwe*






Figure S1: National progress in knowledge of HIV status in sub-Saharan Africa, 2000-2020




Figure S2: Correlation between knowledge of HIV status and ratio of total number of tests relatives to the population aged ≥ 15 years in sub-Saharan Africa, 2020
Each point represents a different country ($n = 40$).




Figure S3: National progress in median time to diagnosis or AIDS-related death in sub-Saharan Africa, 2000-2020




Figure S4: Regional trends in positivity and diagnosis yield, 2000-2020

The positivity corresponds to the proportion of positive tests among all tests, while diagnosis yield corresponds to the proportion of new diagnoses among all tests. HIV prevalence is expressed among the total population aged 15-99 years. The shaded areas correspond to the 95% credible intervals

Table S1: Supplemental HIV testing services programme data sources

Country	Year	Source
Burundi	2003	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2004	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2005	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2006	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2007	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2008	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
	2009	Conseil National de Lutte contre le SIDA, Rapport d'activités sur la lutte contre le SIDA et rapport sur les progrès enregistrés vers un accès universel (Burundi), 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#B
Cameroon	2013	Rapport national de suivi de la déclaration politique sur le VIH/SIDA Cameroun – Global AIDS Response Progress (GARP), 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#C
	2014	Ministry of Public Health, Plan d'accélération de la thérapie ARV au Cameroun 2016-2018, 2015.
Comoros	2018	UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Congo	2013	Conseil National de Lutte contre le SIDA, Rapport d'activités de la riposte au VIH/SIDA – 2013, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#C
Equatorial Guinea	2008	Programa nacional de lucha contra el SIDA, Declaracion de compromiso sobre VIH-SIDA, UNGASS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#E
	2012	Programa nacional de lucha contra el SIDA, informe nacional sobre los progresos realizados en la lucha contra el VIH/SIDA Guinea Ecuatorial, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#E
	2013	Programa nacional de lucha contra el SIDA, informe nacional sobre los progresos realizados en la lucha contra el VIH/SIDA Guinea Ecuatorial, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#E
Eritrea	2004	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2005	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2006	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2007	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2008	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2009	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2010	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2011	National AIDS and Tuberculosis Control Division (NATCoD), 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#E
	2018	UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Gabon	2018	UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Gambia	2010	National AIDS Secretariat Office of the President, Country progress report – The Gambia, 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#G

		2011	National AIDS Secretariat Office of the President, Country progress report – The Gambia, 2012. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries#G
		2013	National AIDS Secretariat Office of the President, The Gambia Global AIDS Response Progress Report, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#G
		2014	National AIDS Secretariat Office of the President, The Gambia Global AIDS Response Progress Report, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#G
Ghana	2011		Ghana AIDS Commission, Country AIDS Response Progress Report – Ghana, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#G
Guinea	2014		Comité National de Lutte contre le SIDA, Rapport national de la riposte VIH/SIDA 2014 - Progrès 2010-2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#G
	2018		UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Lesotho	2005		Lesotho UNGASS Country Report - Status of the national response to the 2001 declaration of commitment on HIV and AIDS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
	2006		Lesotho UNGASS Country Report - Status of the national response to the 2001 declaration of commitment on HIV and AIDS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
	2007		Lesotho UNGASS Country Report - Status of the national response to the 2001 declaration of commitment on HIV and AIDS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
	2008		Lesotho UNGASS Country Report - Status of the national response to the 2001 declaration of commitment on HIV and AIDS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
	2009		Lesotho UNGASS Country Report - Status of the national response to the 2001 declaration of commitment on HIV and AIDS, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
Liberia	2013		Jacobs GP et al. 2017. Did the 2014 Ebola outbreak in Liberia affect HIV testing, linkage to care and ART initiation?, Public Health Action, 7(S1):S70-S75
Madagascar	2010		Comité National de Lutte contre le SIDA, Rapport sur la réponse face au VIH et au SIDA à Madagascar 2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#M
	2011		Comité National de Lutte contre le SIDA, Rapport sur la réponse face au VIH et au SIDA à Madagascar 2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#M
	2012		Comité National de Lutte contre le SIDA, Rapport sur la réponse face au VIH et au SIDA à Madagascar 2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#M
	2013		Comité National de Lutte contre le SIDA, Rapport sur la réponse face au VIH et au SIDA à Madagascar 2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#M
	2014		Comité National de Lutte contre le SIDA, Rapport sur la réponse face au VIH et au SIDA à Madagascar 2014, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#M
	2018		UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Mozambique	2013		Maheu-Giroux M, Marsh K, Doyle C, et al. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the “first 90” from program and survey data. <i>AIDS</i> 2019; 33 : S255–S69.
	2014		Maheu-Giroux M, Marsh K, Doyle C, et al. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the “first 90” from program and survey data. <i>AIDS</i> 2019; 33 : S255–S69.
	2016		Maheu-Giroux M, Marsh K, Doyle C, et al. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the “first 90” from program and survey data. <i>AIDS</i> 2019; 33 : S255–S69.
Namibia	2008		Republic of Namibia Ministry of Health and Social Services, United Nations General Assembly Special Session (UNGASS) Country Report - Reporting Period 2008-2009, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#L
Niger	2018		UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Nigeria	2018		UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Senegal	2008		Conseil National de Lutte contre le SIDA, Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA – Sénégal: 2008-2009, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#S
	2012		Conseil National de Lutte contre le SIDA, Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA – Sénégal: 2012-2013, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#S
	2013		Conseil National de Lutte contre le SIDA, Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA – Sénégal: 2012-2013, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#S

Sierra Leone	2012	Sierra Leone National AIDS Response Progress Report 2014, 2014. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries#S
South Africa	2010	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2011	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2012	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2013	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2014	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2015	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2016	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2017	Johnson L and Dorrington R. 2020. Thembisa version 4.3: A model for evaluating the impact of HIV/AIDS in South Africa. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiE9-bQ09frAhXuhXIEHe0vCvcQFjAAegQIBRAB&url=https%3A%2F%2Fwww.thembisa.org%2Fcontent%2Ffiled%2FThembisa4_3report&usg=AOvVaw1XThc7M7vadKpVmMAXrDKQ
	2018	UNAIDS/WHO/UNICEF. Global AIDS Monitoring, 2020. Accessed at: https://aidsinfo.unaids.org/
Togo	2002	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2003	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2004	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2005	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2006	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2007	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2008	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T

	2009	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Suivi de la déclaration d'engagement sur le VIH et le SIDA - Rapport 2010, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2012	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Rapport annuel des activités de lutte contre le VIH/SIDA au Togo en 2012, 2013.
	2014	Conseil National de Lutte contre le SIDA et les Infections Sexuellement Transmissibles, Rapport d'activité sur la riposte au VIH/SIDA au Togo, 2015. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2015countries#T
	2015	Programme national de lutte contre le SIDA et les IST, Rapport annuel 2015 des activités du PNLS-IST, 2015. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiY3LSw2drAhWNmlkKHdy_AgQQFjAAegQIAxAB&url=http%3A%2F%2Fwww.pnls.tg%2Frapports%2FRAPPORT%2520ANNUEL%2520PNLS%25202015.pdf&usg=AOvVaw2rlRI38FNKwcgBhBHxI_u
Zambia	2006	National AIDS Council, Zambia country report - Monitoring the declaration of commitment on HIV and AIDS and the universal access, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2007	National AIDS Council, Zambia country report - Monitoring the declaration of commitment on HIV and AIDS and the universal access, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2008	National AIDS Council, Zambia country report - Monitoring the declaration of commitment on HIV and AIDS and the universal access, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T
	2009	National AIDS Council, Zambia country report - Monitoring the declaration of commitment on HIV and AIDS and the universal access, 2010. Available from: https://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries#T

Table S2: Checklist of information that should be included in new reports of global health estimates

Item #	Checklist item	Reported on page #
Objectives and funding		
1	Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made.	7, 8
2	List the funding sources for the work.	2
Data Inputs		
<i>For all data inputs from multiple sources that are synthesized as part of the study:</i>		
3	Describe how the data were identified and how the data were accessed.	6
4	Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.	6, 7
5	Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	6, Figure 1, appendix pp 47-50
6	Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).	6, 12, 13
<i>For data inputs that contribute to the analysis but were not synthesized as part of the study:</i>		
7	Describe and give sources for any other data inputs.	6, Figure 1, appendix pp 47-50
<i>For all data inputs:</i>		
8	Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	6 (links provided)
Data analysis		
9	Provide a conceptual overview of the data analysis method. A diagram may be helpful.	5
10	Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	5-8, appendix p 1
11	Describe how candidate models were evaluated and how the final model(s) were selected.	5
12	Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.	appendix pp 2-42
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.	8, 12
14	State how analytic or statistical source code used to generate estimates can be accessed.	8
Results and Discussion		
15	Provide published estimates in a file format from which data can be efficiently extracted.	Table 1, appendix pp 52-57
16	Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals).	2, 9-11, Tables
17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	10-13
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates.	12-13

Table S3: Number of undiagnosed people living with HIV by sex and age stratification and by sub-Saharan African region in 2020 (x 1,000)

Sex	Age group (years)	Sub-Saharan Africa	Western Africa	Central Africa	Eastern Africa	Southern Africa
Men	15-24	346 (318 to 366)	89 (85 to 91)	33 (30 to 35)	163 (150 to 172)	61 (51 to 69)
	25-34	597 (514 to 673)	156 (143 to 169)	53 (40 to 62)	258 (227 to 287)	130 (100 to 156)
	35-49	701 (611 to 788)	211 (191 to 230)	57 (45 to 68)	296 (265 to 327)	136 (104 to 169)
	50-99	264 (231 to 299)	91 (81 to 97)	18 (14 to 21)	109 (96 to 125)	46 (36 to 58)
Women	15-24	563 (492 to 621)	124 (119 to 129)	79 (63 to 91)	222 (200 to 240)	138 (108 to 164)
	25-34	557 (459 to 652)	173 (154 to 188)	92 (66 to 123)	196 (170 to 224)	94 (65 to 125)
	35-49	581 (507 to 664)	166 (156 to 179)	100 (78 to 123)	199 (179 to 221)	115 (87 to 145)
	50-99	234 (202 to 272)	54 (51 to 59)	39 (31 to 46)	77 (71 to 87)	64 (48 to 83)

Numbers in parentheses correspond to 95% credible intervals.

Some small discrepancies are observed between sub-Saharan Africa estimate and the sum of Western, Central, Eastern, and Southern regions estimates because each region-specific estimate is based on independent draws of posterior estimates.

Table S4: Progress in HIV testing related outcomes in sub-Saharan Africa stratified by sex and age group, 2000–2020

Outcome	Year	Overall	Men	Women	15–24 years-old	25–34 years-old	35–49 years-old	50–99 years-old
Proportion of individuals having ever been tested for HIV among overall population (%)	2000	3·6 (3·0 to 4·4)	3·3 (2·6 to 4·0)	4·0 (3·3 to 4·9)	3·2 (2·6 to 3·9)	5·1 (4·2 to 6·2)	3·5 (2·9 to 4·3)	2·6 (2·2 to 3·3)
	2005	11 (10 to 12)	9·9 (9·0 to 11)	13 (12 to 14)	8·8 (7·9 to 9·9)	15 (14 to 17)	12 (11 to 13)	9·1 (8·4 to 10)
	2010	30 (29 to 32)	27 (26 to 29)	33 (32 to 35)	25 (23 to 26)	39 (37 to 41)	33 (31 to 34)	26 (25 to 28)
	2015	41 (40 to 42)	37 (36 to 38)	46 (45 to 47)	29 (28 to 31)	52 (51 to 53)	49 (48 to 50)	40 (38 to 42)
	2020	51 (49 to 54)	46 (43 to 49)	56 (54 to 60)	35 (32 to 39)	61 (59 to 64)	62 (61 to 65)	54 (51 to 57)
Proportion of PLHIV who know their HIV status (%)	2000	5·7 (4·6 to 7·0)	4·6 (3·7 to 5·8)	6·4 (5·1 to 7·9)	4·9 (3·8 to 6·1)	7·2 (5·7 to 8·8)	4·9 (4·0 to 6·1)	3·5 (2·8 to 4·3)
	2005	20 (18 to 22)	16 (14 to 18)	22 (20 to 25)	14 (12 to 16)	24 (21 to 27)	19 (17 to 22)	15 (14 to 17)
	2010	53 (50 to 55)	46 (43 to 48)	57 (54 to 59)	38 (35 to 41)	58 (54 to 60)	55 (52 to 57)	50 (48 to 53)
	2015	71 (69 to 73)	64 (62 to 66)	75 (73 to 77)	51 (49 to 53)	72 (69 to 74)	76 (74 to 78)	75 (73 to 77)
	2020	84 (82 to 86)	79 (76 to 81)	87 (85 to 89)	65 (62 to 69)	81 (79 to 84)	88 (86 to 89)	90 (88 to 91)
Time to diagnosis or AIDS-related death, median (year)	2000	9·6 (9·1 to 10)	9·7 (9·2 to 10)	9·5 (8·9 to 10)	11 (10 to 12)	9·1 (8·5 to 9·5)	8·2 (7·9 to 8·5)	7·6 (7·5 to 7·8)
	2005	7·2 (6·3 to 8·0)	7·7 (6·8 to 8·4)	6·9 (5·9 to 7·8)	7·7 (6·6 to 8·7)	6·8 (5·9 to 7·6)	6·8 (6·3 to 7·3)	6·6 (6·2 to 6·9)
	2010	3·6 (3·2 to 4·1)	4·3 (3·8 to 4·7)	3·2 (2·8 to 3·7)	3·7 (3·2 to 4·3)	3·1 (2·7 to 3·6)	4·0 (3·6 to 4·4)	4·2 (3·9 to 4·6)
	2015	3·0 (2·7 to 3·4)	3·7 (3·4 to 4·2)	2·6 (2·2 to 2·9)	3·2 (2·8 to 3·6)	2·5 (2·2 to 2·9)	3·3 (3·0 to 3·7)	3·5 (3·3 to 3·8)
	2020	2·6 (1·8 to 3·5)	3·3 (2·4 to 4·2)	2·2 (1·5 to 3·0)	2·8 (2·0 to 3·8)	2·2 (1·5 to 3·0)	2·8 (2·0 to 3·6)	2·9 (2·2 to 3·6)
Probability of getting tested within 1 year following infection (%)	2000	2·6 (2·1 to 3·3)	2·1 (1·6 to 2·6)	3·0 (2·3 to 3·8)	2·6 (2·0 to 3·3)	3·2 (2·5 to 4·0)	2·1 (1·6 to 2·6)	1·4 (1·1 to 1·8)
	2005	5·9 (4·5 to 7·7)	4·6 (3·5 to 6·1)	6·7 (5·0 to 8·8)	5·9 (4·5 to 7·8)	6·9 (5·3 to 9·1)	4·5 (3·4 to 5·9)	3·5 (2·7 to 4·6)
	2010	21 (18 to 25)	16 (13 to 19)	25 (21 to 29)	21 (18 to 25)	26 (22 to 31)	16 (13 to 19)	12 (9·9 to 15)
	2015	26 (23 to 30)	19 (16 to 22)	31 (27 to 35)	26 (23 to 29)	32 (28 to 37)	20 (17 to 23)	16 (14 to 19)
	2020	33 (23 to 46)	25 (17 to 36)	39 (27 to 53)	32 (23 to 45)	40 (28 to 54)	27 (17 to 39)	23 (15 to 33)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL (%)	2000	19 (16 to 23)	16 (13 to 19)	22 (18 to 26)	24 (20 to 28)	20 (16 to 24)	12 (10 to 15)	7·2 (5·8 to 8·9)
	2005	35 (29 to 42)	30 (24 to 36)	38 (32 to 45)	42 (35 to 49)	36 (30 to 43)	24 (19 to 29)	16 (13 to 20)
	2010	63 (58 to 66)	56 (51 to 60)	67 (63 to 71)	68 (64 to 72)	67 (63 to 71)	50 (45 to 55)	38 (33 to 42)
	2015	67 (63 to 70)	60 (55 to 63)	72 (68 to 75)	71 (67 to 75)	72 (68 to 76)	56 (51 to 60)	44 (40 to 48)
	2020	71 (62 to 79)	64 (54 to 73)	76 (67 to 83)	74 (66 to 82)	76 (67 to 83)	62 (51 to 71)	52 (41 to 62)
Positivity (% of positive test among all tests)	2000	9·0 (7·7 to 10)	6·6 (5·7 to 7·5)	11 (9·3 to 13)	5·8 (5·1 to 6·6)	13 (11 to 15)	10 (9·0 to 12)	3·4 (2·9 to 3·9)
	2005	11 (9·2 to 14)	7·9 (6·9 to 9·3)	13 (11 to 17)	5·6 (4·8 to 6·8)	16 (13 to 21)	15 (13 to 18)	5·4 (4·8 to 6·2)
	2010	5·9 (4·3 to 8·3)	4·3 (3·3 to 5·8)	6·9 (5·0 to 10)	3·1 (2·4 to 4·2)	7·5 (5·2 to 11)	9·5 (7·3 to 13)	3·8 (3·0 to 4·8)
	2015	4·3 (3·5 to 5·2)	3·6 (3·0 to 4·3)	4·6 (3·8 to 5·8)	2·5 (2·1 to 2·9)	4·8 (3·7 to 6·1)	6·9 (5·7 to 8·5)	3·4 (2·7 to 4·2)
	2020	2·8 (2·1 to 3·9)	2·6 (1·9 to 3·4)	3·0 (2·2 to 4·3)	1·6 (1·3 to 2·0)	3·0 (2·2 to 4·1)	4·6 (3·3 to 6·7)	2·8 (1·9 to 4·3)
Diagnosis yield (% of new diagnoses among all tests)	2000	7·9 (7·0 to 8·6)	6·0 (5·2 to 6·6)	9·4 (8·3 to 10)	5·3 (4·7 to 5·8)	11 (10 to 12)	9·4 (8·2 to 10)	3·1 (2·7 to 3·5)
	2005	7·8 (7·0 to 8·4)	6·2 (5·6 to 6·7)	8·9 (8·0 to 9·7)	4·4 (4·0 to 4·8)	11 (9·4 to 12)	11 (10 to 12)	4·5 (4·0 to 5·0)
	2010	2·8 (2·4 to 3·3)	2·5 (2·2 to 3·0)	3·0 (2·6 to 3·6)	1·8 (1·6 to 2·1)	3·0 (2·5 to 3·5)	4·9 (4·2 to 5·7)	2·5 (2·1 to 2·9)
	2015	1·9 (1·7 to 2·1)	1·9 (1·6 to 2·1)	1·9 (1·7 to 2·1)	1·5 (1·3 to 1·6)	1·8 (1·6 to 2·0)	2·9 (2·5 to 3·3)	1·8 (1·6 to 2·1)
	2020	1·2 (0·9 to 1·5)	1·1 (0·9 to 1·5)	1·2 (0·9 to 1·6)	1·0 (0·8 to 1·2)	1·1 (0·8 to 1·4)	1·7 (1·2 to 2·3)	1·2 (0·8 to 1·7)
Proportion of new HIV diagnoses among all positive tests (%)	2000	89 (77 to 96)	91 (83 to 97)	88 (74 to 96)	92 (82 to 97)	87 (73 to 95)	91 (80 to 97)	92 (83 to 97)
	2005	72 (55 to 86)	79 (65 to 89)	69 (51 to 84)	80 (65 to 91)	66 (48 to 82)	76 (60 to 88)	84 (72 to 92)
	2010	48 (33 to 65)	59 (44 to 73)	44 (29 to 62)	59 (43 to 75)	39 (25 to 58)	52 (38 to 67)	66 (51 to 79)
	2015	44 (37 to 53)	52 (44 to 60)	41 (33 to 50)	60 (52 to 68)	37 (29 to 47)	43 (34 to 51)	55 (43 to 65)
	2020	42 (30 to 55)	45 (34 to 56)	40 (28 to 55)	61 (50 to 73)	36 (25 to 49)	37 (25 to 50)	42 (28 to 59)

PLHIV: people living with HIV, HTS: HIV testing services. Numbers in parentheses correspond to 95% credible intervals.

Table S5: Progress in HIV testing related outcomes in Western Africa stratified by sex and age group, 2000-2020

Outcome	Year	Overall	Men	Women	15-24 years-old	25-34 years-old	35-49 years-old	50-99 years-old
Proportion of individuals having ever been tested for HIV among overall population (%)	2000	3·1 (2·6 to 3·8)	3·1 (2·5 to 3·7)	3·2 (2·6 to 3·8)	2·7 (2·2 to 3·2)	4·7 (3·9 to 5·8)	2·8 (2·3 to 3·4)	2·1 (1·7 to 2·6)
	2005	7·2 (6·6 to 7·8)	6·9 (6·2 to 7·6)	7·4 (6·8 to 8·1)	5·0 (4·4 to 5·6)	11 (9·7 to 12)	8·1 (7·5 to 8·7)	5·5 (5·0 to 6·0)
	2010	19 (18 to 19)	17 (16 to 18)	20 (19 to 21)	13 (12 to 14)	26 (25 to 27)	21 (20 to 22)	15 (14 to 16)
	2015	28 (27 to 29)	24 (23 to 25)	33 (31 to 34)	18 (17 to 20)	37 (36 to 39)	35 (34 to 36)	26 (24 to 27)
	2020	36 (34 to 39)	30 (28 to 32)	42 (40 to 45)	21 (18 to 24)	45 (43 to 48)	47 (46 to 49)	37 (35 to 40)
Proportion of PLHIV who know their HIV status (%)	2000	4·0 (2·8 to 5·2)	3·9 (2·7 to 5·0)	4·2 (2·9 to 5·4)	3·0 (2·0 to 3·8)	5·4 (3·7 to 6·9)	3·5 (2·5 to 4·5)	2·7 (1·9 to 3·5)
	2005	10 (7·7 to 12)	9·2 (6·8 to 11)	11 (8·3 to 13)	5·4 (4·0 to 6·7)	12 (8·5 to 14)	11 (8·2 to 12)	9·7 (8·1 to 11)
	2010	33 (28 to 35)	28 (24 to 31)	36 (31 to 39)	19 (16 to 22)	35 (28 to 38)	34 (31 to 37)	37 (34 to 38)
	2015	52 (48 to 55)	43 (39 to 46)	58 (54 to 60)	32 (29 to 34)	48 (42 to 52)	57 (54 to 59)	61 (59 to 63)
	2020	67 (65 to 69)	55 (52 to 59)	74 (72 to 76)	42 (40 to 44)	58 (55 to 62)	72 (70 to 74)	79 (77 to 81)
Time to diagnosis or AIDS-related death, median (year)	2000	11 (10 to 11)	10 (9·7 to 11)	11 (10 to 11)	12 (12 to 13)	10 (9·5 to 11)	9·0 (8·8 to 9·3)	7·9 (7·8 to 8·1)
	2005	10 (9·4 to 11)	10 (9·4 to 11)	10 (9·5 to 11)	12 (11 to 13)	9·9 (9·1 to 11)	8·8 (8·5 to 9·1)	7·8 (7·5 to 7·9)
	2010	5·5 (4·9 to 6·5)	6·1 (5·4 to 7·0)	5·1 (4·5 to 6·1)	6·2 (5·4 to 7·4)	4·6 (3·9 to 5·7)	5·8 (5·3 to 6·4)	5·7 (5·3 to 6·1)
	2015	5·2 (4·5 to 6·0)	6·0 (5·2 to 6·8)	4·6 (3·9 to 5·4)	6·0 (5·2 to 7·0)	4·3 (3·6 to 5·3)	5·3 (4·7 to 5·9)	5·2 (4·8 to 5·6)
	2020	5·4 (4·1 to 6·5)	6·2 (4·8 to 7·4)	4·8 (3·6 to 6·0)	6·4 (4·9 to 7·8)	4·5 (3·3 to 5·8)	5·1 (4·1 to 6·1)	5·1 (4·3 to 5·7)
Probability of getting tested within 1 year following infection (%)	2000	1·6 (1·1 to 2·1)	1·5 (1·0 to 2·0)	1·7 (1·2 to 2·2)	1·5 (1·0 to 2·0)	2·2 (1·5 to 2·9)	1·2 (0·8 to 1·5)	1·0 (0·7 to 1·3)
	2005	1·8 (1·1 to 2·6)	1·6 (1·0 to 2·3)	1·9 (1·2 to 2·8)	1·7 (1·1 to 2·4)	2·3 (1·5 to 3·3)	1·3 (0·8 to 1·9)	1·1 (0·7 to 1·6)
	2010	11 (7·7 to 14)	9·0 (6·2 to 12)	13 (8·8 to 17)	9·4 (6·3 to 12)	16 (11 to 21)	8·1 (5·6 to 11)	6·2 (4·4 to 8·0)
	2015	13 (9·3 to 17)	9·8 (6·9 to 13)	16 (11 to 20)	10 (7·3 to 14)	19 (13 to 25)	10 (7·3 to 13)	7·8 (5·8 to 10)
	2020	12 (7·0 to 19)	8·4 (4·8 to 14)	15 (8·7 to 23)	9·1 (5·3 to 15)	17 (10 to 28)	9·8 (5·7 to 16)	7·8 (4·8 to 13)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL (%)	2000	13 (9·3 to 16)	12 (8·7 to 15)	14 (9·6 to 17)	17 (12 to 21)	15 (10 to 18)	7·6 (5·4 to 9·5)	5·4 (3·8 to 6·8)
	2005	14 (9·2 to 19)	13 (8·3 to 17)	15 (9·9 to 20)	18 (12 to 24)	15 (10 to 21)	8·3 (5·5 to 12)	6·0 (3·9 to 8·5)
	2010	45 (36 to 51)	40 (31 to 46)	49 (40 to 55)	50 (41 to 56)	52 (43 to 59)	33 (25 to 38)	23 (18 to 28)
	2015	47 (38 to 53)	40 (32 to 47)	52 (43 to 59)	50 (41 to 58)	55 (45 to 62)	36 (28 to 42)	26 (20 to 31)
	2020	44 (32 to 56)	37 (25 to 49)	49 (37 to 61)	45 (33 to 58)	52 (39 to 65)	35 (24 to 47)	25 (16 to 35)
Positivity (% of positive test among all tests)	2000	3·0 (2·1 to 3·5)	2·5 (1·7 to 2·9)	3·5 (2·4 to 4·1)	1·4 (1·0 to 1·6)	4·2 (2·9 to 5·0)	4·1 (2·9 to 4·8)	1·8 (1·3 to 2·1)
	2005	4·0 (3·3 to 4·5)	2·9 (2·4 to 3·4)	4·9 (4·1 to 5·5)	1·3 (1·0 to 1·6)	4·8 (3·7 to 5·6)	7·0 (6·1 to 7·9)	4·5 (3·8 to 5·4)
	2010	2·6 (2·0 to 3·2)	2·0 (1·6 to 2·5)	3·0 (2·3 to 3·8)	1·1 (0·9 to 1·3)	2·8 (2·0 to 3·7)	4·6 (3·7 to 5·6)	2·7 (2·2 to 3·3)
	2015	2·2 (1·7 to 2·7)	1·9 (1·4 to 2·3)	2·4 (1·8 to 3·0)	1·0 (0·8 to 1·2)	2·1 (1·5 to 2·6)	4·0 (3·1 to 4·9)	2·7 (2·1 to 3·4)
	2020	1·9 (1·3 to 2·7)	1·7 (1·3 to 2·4)	2·0 (1·4 to 2·9)	0·9 (0·7 to 1·3)	1·6 (1·2 to 2·2)	3·2 (2·3 to 4·6)	2·7 (1·8 to 4·0)
Diagnosis yield (% of new diagnoses among all tests)	2000	2·6 (1·8 to 2·9)	2·1 (1·5 to 2·5)	2·9 (2·1 to 3·4)	1·2 (0·9 to 1·4)	3·5 (2·4 to 4·0)	3·6 (2·6 to 4·2)	1·7 (1·2 to 1·9)
	2005	3·2 (2·7 to 3·6)	2·3 (1·9 to 2·6)	3·9 (3·3 to 4·4)	1·1 (0·9 to 1·3)	3·5 (2·7 to 4·0)	5·6 (4·9 to 6·6)	4·0 (3·4 to 5·0)
	2010	1·5 (1·2 to 1·7)	1·3 (1·1 to 1·5)	1·6 (1·3 to 1·9)	0·7 (0·6 to 0·8)	1·3 (1·1 to 1·6)	2·8 (2·4 to 3·3)	1·9 (1·5 to 2·3)
	2015	1·1 (0·9 to 1·3)	1·0 (0·9 to 1·2)	1·1 (0·9 to 1·3)	0·6 (0·5 to 0·7)	0·9 (0·7 to 1·0)	1·9 (1·6 to 2·4)	1·4 (1·1 to 1·8)
	2020	1·0 (0·7 to 1·5)	1·0 (0·7 to 1·4)	1·0 (0·6 to 1·6)	0·6 (0·4 to 1·0)	0·7 (0·5 to 1·0)	1·7 (1·1 to 2·6)	1·5 (0·9 to 2·4)
Proportion of new HIV diagnoses among all positive tests (%)	2000	86 (79 to 94)	87 (80 to 95)	85 (78 to 94)	91 (86 to 96)	83 (74 to 93)	88 (83 to 95)	91 (87 to 96)
	2005	79 (71 to 90)	80 (72 to 91)	79 (71 to 89)	86 (79 to 93)	74 (65 to 87)	81 (73 to 90)	89 (84 to 94)
	2010	56 (46 to 73)	65 (53 to 81)	53 (43 to 69)	67 (59 to 81)	47 (38 to 67)	61 (49 to 75)	70 (57 to 82)
	2015	48 (38 to 61)	54 (44 to 68)	45 (35 to 58)	60 (51 to 71)	42 (32 to 57)	49 (38 to 62)	53 (41 to 65)
	2020	52 (38 to 68)	56 (44 to 70)	50 (35 to 68)	68 (55 to 81)	44 (31 to 60)	53 (38 to 69)	55 (39 to 72)

PLHIV: people living with HIV, HTS: HIV testing services. Numbers in parentheses correspond to 95% credible intervals.

Table S6: Progress in HIV testing related outcomes in Central Africa stratified by sex and age group, 2000-2020

Outcome	Year	Overall	Men	Women	15-24 years-old	25-34 years-old	35-49 years-old	50-99 years-old
Proportion of individuals having ever been tested for HIV among overall population (%)	2000	1·9 (1·3 to 2·6)	1·7 (1·2 to 2·3)	2·0 (1·4 to 2·8)	1·6 (1·1 to 2·2)	2·5 (1·8 to 3·5)	1·9 (1·3 to 2·5)	1·5 (1·0 to 2·0)
	2005	7·8 (6·6 to 9·2)	7·0 (5·8 to 8·4)	8·6 (7·3 to 10)	6·0 (5·0 to 7·3)	11 (9·0 to 13)	8·5 (7·3 to 10)	6·6 (5·6 to 7·8)
	2010	19 (17 to 22)	17 (15 to 20)	21 (19 to 23)	13 (12 to 16)	26 (23 to 29)	23 (21 to 25)	18 (16 to 20)
	2015	29 (28 to 30)	26 (24 to 27)	32 (31 to 33)	18 (17 to 19)	37 (35 to 39)	37 (35 to 38)	29 (26 to 32)
	2020	42 (39 to 48)	39 (34 to 44)	47 (42 to 53)	26 (22 to 33)	52 (47 to 59)	54 (50 to 59)	46 (41 to 51)
Proportion of PLHIV who know their HIV status (%)	2000	3·2 (2·0 to 4·6)	3·1 (2·0 to 4·5)	3·3 (2·1 to 4·8)	2·7 (1·7 to 4·0)	3·9 (2·5 to 5·6)	2·9 (1·8 to 4·2)	2·4 (1·5 to 3·4)
	2005	15 (12 to 18)	15 (12 to 18)	16 (12 to 18)	11 (8·8 to 14)	18 (14 to 22)	15 (12 to 17)	13 (10 to 15)
	2010	37 (32 to 41)	36 (32 to 40)	38 (32 to 42)	21 (17 to 25)	40 (34 to 45)	41 (36 to 44)	38 (35 to 42)
	2015	53 (47 to 56)	50 (45 to 54)	54 (48 to 58)	30 (25 to 33)	53 (45 to 57)	59 (54 to 63)	59 (55 to 63)
	2020	70 (64 to 76)	68 (63 to 74)	71 (65 to 78)	45 (38 to 54)	67 (58 to 76)	76 (71 to 81)	79 (76 to 83)
Time to diagnosis or AIDS-related death, median (year)	2000	11 (10 to 12)	11 (10 to 11)	11 (10 to 12)	13 (12 to 14)	10 (9·7 to 11)	9·0 (8·7 to 9·3)	7·9 (7·7 to 8·1)
	2005	8·2 (7·1 to 9·3)	8·2 (7·0 to 9·2)	8·3 (7·1 to 9·4)	9·3 (7·9 to 11)	7·6 (6·5 to 8·7)	7·4 (6·7 to 8·0)	6·7 (6·2 to 7·2)
	2010	6·1 (5·2 to 7·3)	6·1 (5·2 to 7·2)	6·0 (5·1 to 7·3)	6·8 (5·9 to 8·3)	5·3 (4·4 to 6·6)	5·8 (5·0 to 6·6)	5·6 (5·0 to 6·2)
	2015	4·7 (3·9 to 6·0)	5·2 (4·4 to 6·5)	4·5 (3·7 to 5·8)	5·2 (4·3 to 6·6)	4·0 (3·1 to 5·4)	4·8 (4·0 to 5·9)	4·9 (4·2 to 5·6)
	2020	3·9 (2·2 to 6·0)	4·6 (2·8 to 6·5)	3·6 (1·9 to 5·7)	4·3 (2·4 to 6·6)	3·2 (1·7 to 5·5)	4·0 (2·4 to 5·8)	4·1 (2·6 to 5·4)
Probability of getting tested within 1 year following infection (%)	2000	1·5 (1·0 to 2·1)	1·3 (0·9 to 1·9)	1·5 (1·0 to 2·2)	1·5 (0·9 to 2·1)	1·8 (1·2 to 2·6)	1·2 (0·8 to 1·7)	1·0 (0·7 to 1·5)
	2005	5·1 (3·6 to 7·1)	4·6 (3·2 to 6·6)	5·3 (3·7 to 7·4)	4·9 (3·5 to 6·8)	6·2 (4·3 to 8·8)	4·1 (2·8 to 5·7)	3·6 (2·5 to 4·9)
	2010	9·3 (6·5 to 13)	8·1 (5·7 to 12)	9·9 (6·8 to 14)	8·5 (5·9 to 12)	12 (8·1 to 18)	7·5 (5·1 to 11)	6·2 (4·3 to 8·8)
	2015	12 (7·8 to 18)	9·7 (6·3 to 14)	13 (8·4 to 20)	11 (6·9 to 16)	16 (9·9 to 24)	9·7 (6·2 to 15)	8·0 (5·3 to 13)
	2020	16 (7·6 to 34)	13 (6·4 to 26)	17 (8·3 to 37)	14 (7·0 to 30)	20 (9·7 to 42)	13 (6·3 to 30)	11 (5·6 to 25)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL (%)	2000	12 (8·3 to 17)	11 (7·8 to 16)	12 (8·5 to 17)	15 (10 to 20)	13 (8·6 to 17)	7·7 (5·3 to 11)	5·6 (3·8 to 7·7)
	2005	30 (22 to 38)	29 (22 to 37)	30 (23 to 38)	34 (26 to 42)	32 (24 to 41)	21 (15 to 27)	16 (12 to 21)
	2010	43 (34 to 51)	41 (32 to 49)	44 (34 to 52)	47 (37 to 54)	48 (37 to 56)	33 (25 to 41)	24 (18 to 31)
	2015	52 (41 to 60)	47 (36 to 56)	54 (43 to 62)	56 (45 to 63)	57 (45 to 66)	40 (29 to 49)	30 (21 to 38)
	2020	59 (39 to 75)	52 (34 to 70)	62 (41 to 78)	63 (43 to 78)	64 (42 to 81)	48 (28 to 67)	37 (21 to 56)
Positivity (% of positive test among all tests)	2000	4·6 (3·5 to 5·2)	3·1 (2·3 to 3·6)	5·8 (4·4 to 6·5)	3·1 (2·4 to 3·6)	6·6 (5·0 to 7·6)	5·1 (3·8 to 5·9)	2·1 (1·6 to 2·4)
	2005	5·4 (4·2 to 6·7)	3·7 (2·9 to 4·5)	6·7 (5·2 to 8·5)	2·9 (2·3 to 3·7)	7·8 (6·1 to 10)	6·8 (5·4 to 8·2)	2·9 (2·4 to 3·4)
	2010	5·0 (3·6 to 6·9)	3·4 (2·6 to 4·4)	6·1 (4·3 to 8·6)	2·3 (1·8 to 3·1)	6·5 (4·3 to 9·6)	7·3 (5·4 to 9·6)	3·2 (2·5 to 4·1)
	2015	3·4 (2·4 to 4·7)	2·3 (1·7 to 3·1)	4·2 (2·8 to 5·9)	1·6 (1·2 to 2·1)	3·9 (2·5 to 5·9)	5·6 (3·8 to 7·4)	2·8 (2·0 to 3·7)
	2020	2·2 (1·4 to 3·3)	1·5 (1·0 to 2·2)	2·7 (1·7 to 4·1)	1·1 (0·8 to 1·4)	2·3 (1·4 to 3·7)	3·5 (2·1 to 5·3)	2·1 (1·3 to 3·3)
Diagnosis yield (% of new diagnoses among all tests)	2000	4·2 (3·2 to 4·7)	2·8 (2·1 to 3·3)	5·3 (4·1 to 5·9)	2·9 (2·3 to 3·3)	6·0 (4·6 to 6·8)	4·8 (3·6 to 5·4)	2·0 (1·5 to 2·3)
	2005	3·8 (3·1 to 4·3)	2·7 (2·2 to 3·1)	4·6 (3·8 to 5·2)	2·2 (1·8 to 2·5)	5·2 (4·2 to 5·8)	5·1 (4·2 to 5·7)	2·4 (2·0 to 2·7)
	2010	2·6 (2·1 to 3·0)	2·0 (1·7 to 2·3)	3·0 (2·4 to 3·5)	1·5 (1·2 to 1·7)	2·9 (2·2 to 3·5)	3·9 (3·2 to 4·7)	2·1 (1·7 to 2·6)
	2015	1·6 (1·2 to 1·8)	1·1 (0·9 to 1·3)	1·9 (1·4 to 2·3)	1·0 (0·8 to 1·1)	1·6 (1·1 to 1·9)	2·4 (1·8 to 3·1)	1·5 (1·1 to 1·9)
	2020	0·9 (0·6 to 1·3)	0·7 (0·4 to 1·0)	1·1 (0·7 to 1·5)	0·7 (0·5 to 0·9)	0·9 (0·5 to 1·2)	1·3 (0·8 to 2·1)	0·9 (0·5 to 1·5)
Proportion of new HIV diagnoses among all positive tests (%)	2000	93 (85 to 97)	93 (86 to 97)	92 (85 to 97)	94 (87 to 98)	91 (83 to 96)	93 (87 to 97)	95 (90 to 98)
	2005	71 (55 to 86)	75 (59 to 88)	70 (53 to 85)	76 (60 to 89)	66 (49 to 83)	75 (61 to 88)	82 (70 to 92)
	2010	52 (36 to 71)	59 (43 to 77)	49 (34 to 70)	66 (49 to 83)	44 (29 to 66)	54 (39 to 72)	66 (49 to 80)
	2015	46 (33 to 59)	49 (36 to 60)	45 (32 to 59)	65 (50 to 76)	41 (27 to 57)	44 (31 to 55)	53 (39 to 62)
	2020	42 (24 to 57)	47 (30 to 61)	40 (23 to 55)	62 (42 to 75)	38 (20 to 55)	38 (23 to 52)	43 (27 to 58)

PLHIV: people living with HIV, HTS: HIV testing services. Numbers in parentheses correspond to 95% credible intervals.

Table S7: Progress in HIV testing related outcomes in Eastern Africa stratified by sex and age group, 2000-2020

Outcome	Year	Overall	Men	Women	15-24 years-old	25-34 years-old	35-49 years-old	50-99 years-old
Proportion of individuals having ever been tested for HIV among overall population (%)	2000	3·3 (2·8 to 3·9)	2·9 (2·4 to 3·4)	3·7 (3·1 to 4·4)	3·3 (2·8 to 3·9)	4·6 (3·9 to 5·4)	2·8 (2·4 to 3·4)	2·1 (1·7 to 2·5)
	2005	13 (12 to 14)	11 (9·9 to 12)	14 (13 to 15)	11 (10 to 12)	17 (16 to 19)	12 (11 to 13)	8·6 (7·9 to 9·4)
	2010	41 (39 to 42)	37 (35 to 39)	44 (43 to 46)	37 (35 to 39)	51 (49 to 53)	41 (40 to 43)	32 (30 to 34)
	2015	53 (52 to 54)	49 (47 to 50)	58 (57 to 59)	41 (40 to 42)	66 (65 to 67)	61 (60 to 62)	49 (48 to 51)
	2020	64 (62 to 66)	59 (57 to 61)	68 (66 to 71)	48 (45 to 52)	74 (73 to 76)	74 (73 to 76)	65 (63 to 67)
Proportion of PLHIV who know their HIV status (%)	2000	4·8 (4·0 to 5·8)	4·0 (3·3 to 4·8)	5·4 (4·4 to 6·5)	4·1 (3·3 to 4·9)	6·1 (5·1 to 7·4)	4·1 (3·4 to 4·9)	3·0 (2·4 to 3·6)
	2005	19 (17 to 21)	16 (14 to 17)	21 (19 to 23)	14 (12 to 16)	23 (20 to 25)	18 (16 to 20)	14 (12 to 15)
	2010	56 (53 to 58)	49 (47 to 51)	60 (57 to 62)	44 (41 to 47)	60 (57 to 63)	57 (55 to 60)	53 (50 to 55)
	2015	74 (72 to 75)	67 (65 to 69)	78 (77 to 80)	57 (55 to 59)	74 (72 to 76)	78 (76 to 79)	77 (75 to 79)
	2020	86 (85 to 88)	81 (79 to 83)	90 (89 to 91)	71 (69 to 74)	84 (83 to 86)	89 (88 to 90)	92 (91 to 93)
Time to diagnosis or AIDS-related death, median (year)	2000	11 (10 to 11)	11 (10 to 11)	11 (10 to 11)	12 (12 to 13)	10 (9·8 to 11)	9·0 (8·8 to 9·2)	8·0 (7·8 to 8·0)
	2005	7·3 (6·3 to 8·2)	7·8 (6·9 to 8·5)	6·9 (5·8 to 7·9)	7·6 (6·4 to 8·8)	6·9 (5·9 to 7·8)	7·3 (6·7 to 7·8)	6·8 (6·4 to 7·1)
	2010	3·2 (2·8 to 3·6)	4·0 (3·6 to 4·4)	2·6 (2·3 to 3·0)	3·1 (2·7 to 3·5)	2·8 (2·4 to 3·2)	4·0 (3·6 to 4·4)	4·2 (3·9 to 4·6)
	2015	2·6 (2·4 to 2·9)	3·4 (3·1 to 3·7)	2·0 (1·8 to 2·3)	2·6 (2·3 to 2·9)	2·2 (2·0 to 2·4)	3·2 (2·9 to 3·4)	3·4 (3·2 to 3·7)
	2020	2·0 (1·5 to 2·7)	2·7 (2·0 to 3·5)	1·5 (1·1 to 2·1)	2·0 (1·4 to 2·7)	1·7 (1·3 to 2·3)	2·4 (1·8 to 3·1)	2·6 (2·0 to 3·3)
Probability of getting tested within 1 year following infection (%)	2000	1·7 (1·4 to 2·1)	1·5 (1·2 to 1·8)	1·9 (1·6 to 2·3)	1·9 (1·5 to 2·3)	2·1 (1·7 to 2·5)	1·2 (1·0 to 1·4)	0·9 (0·8 to 1·1)
	2005	5·8 (4·4 to 7·6)	4·7 (3·6 to 6·1)	6·5 (4·9 to 8·6)	6·2 (4·7 to 8·2)	6·8 (5·2 to 8·9)	3·8 (2·9 to 5·0)	3·1 (2·4 to 4·1)
	2010	25 (21 to 29)	18 (15 to 22)	30 (25 to 35)	27 (22 to 32)	29 (24 to 35)	16 (13 to 19)	12 (10 to 15)
	2015	31 (28 to 35)	22 (19 to 24)	38 (34 to 42)	33 (29 to 36)	37 (33 to 41)	21 (19 to 24)	17 (15 to 19)
	2020	40 (29 to 52)	28 (20 to 39)	48 (36 to 61)	41 (30 to 53)	47 (35 to 60)	29 (20 to 40)	24 (17 to 34)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL (%)	2000	14 (11 to 16)	11 (9·6 to 14)	15 (12 to 18)	17 (14 to 20)	14 (12 to 16)	7·6 (6·3 to 9·0)	5·1 (4·2 to 6·2)
	2005	35 (29 to 42)	30 (24 to 36)	38 (32 to 46)	43 (36 to 50)	36 (29 to 43)	21 (17 to 27)	15 (12 to 19)
	2010	66 (62 to 70)	58 (54 to 63)	71 (68 to 75)	73 (69 to 76)	71 (67 to 74)	50 (45 to 54)	38 (34 to 42)
	2015	71 (68 to 74)	63 (59 to 66)	77 (74 to 79)	76 (74 to 79)	76 (73 to 78)	58 (54 to 61)	45 (41 to 49)
	2020	77 (70 to 83)	69 (61 to 77)	82 (76 to 87)	81 (74 to 87)	81 (75 to 86)	66 (57 to 74)	55 (45 to 64)
Positivity (% of positive test among all tests)	2000	11 (9·6 to 12)	8·5 (7·6 to 9·3)	12 (11 to 14)	5·2 (4·6 to 5·8)	17 (15 to 18)	15 (13 to 16)	5·9 (5·2 to 6·5)
	2005	10 (9·1 to 12)	7·9 (7·2 to 8·9)	12 (10 to 14)	4·5 (3·9 to 5·3)	15 (13 to 18)	16 (15 to 18)	6·7 (6·1 to 7·4)
	2010	5·6 (4·2 to 7·5)	4·0 (3·2 to 5·2)	6·6 (4·8 to 9·1)	2·8 (2·1 to 3·7)	7·3 (5·2 to 11)	9·8 (7·6 to 13)	4·2 (3·4 to 5·3)
	2015	4·0 (3·5 to 4·6)	3·5 (3·1 to 4·1)	4·3 (3·7 to 5·0)	2·4 (2·1 to 2·7)	4·5 (3·8 to 5·4)	6·7 (5·8 to 7·9)	3·7 (2·9 to 4·6)
	2020	2·5 (1·9 to 3·3)	2·3 (1·8 to 2·9)	2·6 (2·0 to 3·6)	1·5 (1·2 to 1·9)	2·7 (2·1 to 3·5)	4·0 (2·9 to 5·6)	2·8 (1·9 to 4·2)
Diagnosis yield (% of new diagnoses among all tests)	2000	9·7 (8·8 to 11)	7·9 (7·1 to 8·5)	11 (10 to 12)	4·8 (4·3 to 5·2)	15 (14 to 16)	14 (12 to 15)	5·6 (5·0 to 6·1)
	2005	7·6 (7·0 to 8·1)	6·4 (5·9 to 6·9)	8·5 (7·7 to 9·1)	3·6 (3·2 to 3·8)	10 (9·5 to 11)	13 (12 to 14)	5·8 (5·3 to 6·4)
	2010	2·4 (2·1 to 2·9)	2·2 (1·9 to 2·7)	2·6 (2·2 to 3·0)	1·5 (1·2 to 1·7)	2·6 (2·1 to 3·0)	4·8 (4·0 to 5·7)	2·7 (2·3 to 3·3)
	2015	1·7 (1·6 to 1·8)	1·7 (1·5 to 1·9)	1·7 (1·5 to 1·8)	1·3 (1·2 to 1·4)	1·5 (1·4 to 1·7)	2·7 (2·4 to 3)	2·0 (1·7 to 2·3)
	2020	1·0 (0·8 to 1·3)	1·0 (0·8 to 1·2)	1·0 (0·8 to 1·3)	0·9 (0·7 to 1·1)	1·0 (0·8 to 1·2)	1·4 (1·1 to 1·8)	1·1 (0·8 to 1·5)
Proportion of new HIV diagnoses among all positive tests (%)	2000	91 (85 to 95)	93 (89 to 96)	90 (83 to 95)	92 (87 to 96)	89 (82 to 94)	93 (89 to 96)	95 (92 to 97)
	2005	74 (61 to 84)	81 (71 to 88)	70 (57 to 82)	79 (68 to 88)	67 (54 to 80)	79 (68 to 87)	87 (79 to 92)
	2010	44 (32 to 59)	55 (43 to 68)	39 (28 to 55)	53 (39 to 68)	35 (24 to 50)	49 (38 to 62)	65 (52 to 76)
	2015	42 (37 to 48)	49 (43 to 55)	39 (33 to 45)	55 (49 to 62)	34 (29 to 41)	40 (34 to 46)	53 (43 to 65)
	2020	41 (30 to 52)	44 (34 to 54)	39 (28 to 52)	59 (49 to 70)	35 (26 to 47)	34 (24 to 46)	38 (25 to 56)

PLHIV: people living with HIV, HTS: HIV testing services. Numbers in parentheses correspond to 95% credible intervals.

Table S8: Progress in HIV testing related outcomes in Southern Africa stratified by sex and age group, 2000-2020

Outcome	Year	Overall	Men	Women	15-24 years-old	25-34 years-old	35-49 years-old	50-99 years-old
Proportion of individuals having ever been tested for HIV among overall population (%)	2000	10 (8·3 to 12·9)	8·5 (6·7 to 11)	12 (9·8 to 15)	8·8 (6·9 to 11)	14 (11 to 17)	11 (8·5 to 13)	8·4 (6·8 to 11)
	2005	30 (29 to 32)	25 (23 to 27)	34 (33 to 36)	22 (21 to 24)	39 (37 to 41)	34 (32 to 36)	27 (26 to 29)
	2010	59 (58 to 61)	52 (50 to 54)	65 (64 to 67)	44 (42 to 46)	69 (67 to 70)	68 (66 to 70)	58 (56 to 61)
	2015	75 (74 to 75)	68 (67 to 69)	80 (79 to 81)	53 (52 to 54)	82 (81 to 83)	86 (85 to 87)	79 (77 to 81)
	2020	85 (83 to 88)	80 (77 to 84)	90 (87 to 92)	62 (57 to 70)	90 (88 to 93)	95 (93 to 96)	92 (90 to 93)
Proportion of PLHIV who know their HIV status (%)	2000	9·3 (7·5 to 12)	6·9 (5·4 to 8·7)	11 (8·7 to 14)	7·0 (5·5 to 8·9)	11 (9·1 to 14)	8·9 (7·2 to 11)	7·8 (6·4 to 9·5)
	2005	27 (25 to 30)	21 (19 to 24)	31 (28 to 34)	18 (16 to 20)	32 (30 to 35)	28 (26 to 31)	25 (23 to 27)
	2010	60 (58 to 63)	51 (48 to 54)	66 (63 to 68)	41 (38 to 44)	65 (63 to 68)	64 (61 to 67)	59 (56 to 62)
	2015	79 (77 to 80)	72 (70 to 74)	82 (81 to 84)	55 (52 to 57)	80 (78 to 81)	84 (82 to 85)	81 (79 to 83)
	2020	90 (88 to 92)	87 (84 to 90)	92 (90 to 94)	70 (65 to 76)	89 (87 to 92)	93 (92 to 95)	93 (91 to 95)
Time to diagnosis or AIDS-related death, median (year)	2000	7·7 (7·0 to 8·4)	8·2 (7·6 to 8·7)	7·4 (6·6 to 8·1)	8·5 (7·7 to 9·3)	7·1 (6·4 to 7·8)	6·8 (6·3 to 7·2)	6·4 (6·1 to 6·6)
	2005	5·9 (5·1 to 6·6)	6·5 (5·8 to 7·2)	5·4 (4·6 to 6·2)	6·4 (5·5 to 7·2)	5·3 (4·6 to 6·1)	5·6 (4·9 to 6·2)	5·4 (4·9 to 5·8)
	2010	2·8 (2·5 to 3·1)	3·5 (3·2 to 3·8)	2·4 (2·1 to 2·7)	3·1 (2·8 to 3·5)	2·4 (2·1 to 2·6)	2·7 (2·4 to 3·0)	3·1 (2·8 to 3·4)
	2015	2·2 (1·9 to 2·4)	2·7 (2·4 to 3·0)	1·8 (1·6 to 2·1)	2·5 (2·2 to 2·7)	1·8 (1·6 to 2·0)	2·0 (1·8 to 2·3)	2·4 (2·1 to 2·6)
	2020	1·5 (0·9 to 2·3)	1·8 (1·1 to 2·7)	1·3 (0·8 to 2·0)	1·7 (1·0 to 2·7)	1·2 (0·7 to 1·9)	1·4 (0·9 to 2·2)	1·7 (1·0 to 2·5)
Probability of getting tested within 1 year following infection (%)	2000	4·2 (3·3 to 5·3)	3·1 (2·4 to 3·9)	4·9 (3·9 to 6·3)	3·9 (3·0 to 5·0)	5·1 (4·0 to 6·5)	3·6 (2·8 to 4·6)	3·1 (2·5 to 3·9)
	2005	7·5 (5·8 to 9·7)	5·7 (4·4 to 7·4)	8·7 (6·6 to 11)	7·1 (5·5 to 9·2)	9·2 (7·1 to 12)	6·4 (4·9 to 8·3)	5·6 (4·3 to 7·3)
	2010	23 (20 to 26)	17 (15 to 19)	27 (23 to 31)	20 (18 to 23)	29 (25 to 33)	21 (18 to 25)	17 (14 to 20)
	2015	28 (25 to 32)	22 (19 to 25)	33 (29 to 37)	25 (22 to 29)	35 (31 to 39)	27 (23 to 31)	22 (19 to 25)
	2020	40 (26 to 60)	32 (20 to 50)	44 (29 to 65)	36 (23 to 56)	49 (33 to 69)	38 (24 to 57)	32 (20 to 49)
Probability of getting tested before reaching a CD4 count lower than 350 cells per µL (%)	2000	30 (25 to 35)	23 (19 to 28)	34 (29 to 40)	34 (29 to 40)	31 (25 to 37)	20 (17 to 25)	15 (12 to 18)
	2005	43 (37 to 50)	36 (30 to 42)	48 (41 to 55)	49 (43 to 55)	45 (39 to 52)	32 (26 to 39)	24 (20 to 30)
	2010	69 (66 to 72)	61 (58 to 65)	74 (71 to 77)	72 (69 to 74)	74 (71 to 77)	62 (58 to 66)	49 (45 to 53)
	2015	75 (72 to 77)	68 (65 to 71)	79 (76 to 81)	76 (74 to 79)	79 (77 to 82)	69 (65 to 72)	57 (53 to 61)
	2020	81 (72 to 89)	77 (65 to 86)	84 (75 to 91)	83 (74 to 90)	86 (78 to 92)	78 (66 to 86)	67 (53 to 78)
Positivity (% of positive test among all tests)	2000	15 (13 to 19)	12 (10 to 14)	18 (15 to 22)	14 (13 to 16)	24 (21 to 29)	14 (12 to 16)	3·3 (2·7 to 4·1)
	2005	20 (16 to 26)	15 (13 to 19)	23 (19 to 31)	14 (12 to 17)	31 (26 to 41)	21 (18 to 27)	5·3 (4·5 to 6·8)
	2010	13 (9·0 to 22)	10 (7·7 to 15)	15 (9·9 to 25)	9·5 (7·4 to 14)	19 (12 to 32)	16 (11 to 25)	4·1 (3·0 to 5·9)
	2015	9·2 (7·1 to 13)	7·6 (6·2 to 9·8)	10 (7·7 to 14)	6·5 (5·5 to 8·0)	12 (8·9 to 17)	13 (9·9 to 17)	3·5 (2·8 to 5·0)
	2020	5·5 (3·8 to 8·4)	5·2 (3·6 to 7·5)	5·8 (3·9 to 9·0)	3·5 (2·7 to 4·6)	6·3 (4·2 to 9·8)	8·4 (5·5 to 13)	3·0 (2·0 to 5·4)
Diagnosis yield (% of new diagnoses among all tests)	2000	13 (12 to 14)	11 (9·4 to 11)	15 (14 to 16)	13 (12 to 14)	20 (18 to 22)	12 (11 to 13)	2·8 (2·5 to 3·1)
	2005	14 (12 to 15)	11 (11 to 12)	15 (13 to 16)	11 (10 to 12)	20 (16 to 22)	15 (13 to 16)	4·1 (3·8 to 4·4)
	2010	6·9 (6·2 to 7·5)	6·5 (5·9 to 7·1)	7·2 (6·4 to 7·9)	6·6 (6·1 to 7·2)	8·3 (7·1 to 9·3)	8·5 (7·6 to 9·4)	2·7 (2·4 to 3·0)
	2015	4·4 (4·1 to 4·6)	4·3 (3·9 to 4·6)	4·4 (4·1 to 4·7)	4·5 (4·2 to 4·8)	4·8 (4·4 to 5·2)	5·5 (5·1 to 5·9)	2·0 (1·9 to 2·2)
	2020	2·2 (1·6 to 2·9)	2·2 (1·5 to 3·0)	2·2 (1·6 to 2·8)	2·3 (1·7 to 2·9)	2·2 (1·5 to 2·9)	2·8 (1·9 to 3·8)	1·2 (0·9 to 1·8)
Proportion of new HIV diagnoses among all positive tests (%)	2000	87 (70 to 97)	91 (77 to 98)	86 (67 to 97)	91 (78 to 98)	85 (65 to 97)	88 (72 to 98)	87 (70 to 98)
	2005	70 (48 to 87)	78 (58 to 91)	67 (44 to 86)	81 (61 to 93)	64 (40 to 84)	72 (50 to 88)	78 (58 to 90)
	2010	53 (31 to 76)	64 (41 to 82)	49 (27 to 73)	70 (46 to 88)	44 (23 to 70)	54 (33 to 75)	67 (46 to 84)
	2015	47 (34 to 60)	56 (43 to 68)	43 (31 to 57)	70 (57 to 80)	40 (28 to 54)	43 (31 to 56)	58 (41 to 73)
	2020	39 (25 to 55)	42 (28 to 56)	37 (23 to 55)	66 (50 to 79)	35 (22 to 51)	34 (20 to 49)	41 (22 to 61)

PLHIV: people living with HIV, HTS: HIV testing services. Numbers in parentheses correspond to 95% credible intervals.